Currently out of the existing stock ratings of Salim Syed, 169 are a BUY (80.86%), 40 are a HOLD (19.14%).

Salim Syed

Work Performance Price Targets & Ratings Chart

Analyst Salim Syed, currently employed at MIZUHO, carries an average stock price target met ratio of 64.42% that have a potential upside of 46.28% achieved within 335 days.

Salim Syed’s has documented 404 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CYTK, Cytokinetics at 24-Jun-2026.

Wall Street Analyst Salim Syed

Analyst best performing recommendations are on UBX (UNITY BIOTECHNOLOGY).
The best stock recommendation documented was for UBX (UNITY BIOTECHNOLOGY) at 8/17/2020. The price target of $40 was fulfilled within 1 day with a profit of $1.5 (3.61%) receiving and performance score of 36.14.

Average potential price target upside

of $38.83 (27.37%) on AMGN (AMGEN).
of $26.68 (52.45%) on CRSP (CRISPR THERAPEUTICS AG).
of $25.92 (12.62%) on BIIB (BIOGEN).

AMGN Amgen ASMB Assembly Biosciences BBIO BridgeBio Pharma BIIB Biogen BMY Bristol-Myers Squibb Company CELG Celgene CYTK Cytokinetics GILD Gilead Sciences NKTX Nkarta UBX Unity Biotechnology WVE Wave Life Sciences Ltd ATRA Atara Biotherapeutics CHRS Coherus BioSciences CRSP Crispr Therapeutics AG PCVX Vaxcyte ELVN Enliven Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Terence Flynn (MORGAN STANLEY)